Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10087259 | 0.89 | CYP1A1 (0.47) | L3MBTL1CA1CA2CA9POLB | |
| SCHEMBL10087260 | 0.84 | CA1 (0.36) | CA1CA2CA9POLBTP53 | |
| SCHEMBL10087202 | 0.82 | L3MBTL1 (0.53) | L3MBTL1CA1CA2CA9POLB | |
| SCHEMBL13578707 | 0.82 | CA1 (0.41) | CA1CA2CA9ALDH1A1GAA | |
| SCHEMBL13622824 | 0.81 | SMN1; SMN2 (0.42) | L3MBTL1CA1CA2CA9POLB | |
| SCHEMBL13474635 | 0.74 | LPL (0.38) | CA1CA2CA9CA12CA4 | |
| SCHEMBL13100287 | 0.73 | CA1 (0.36) | CA1CA2CA9ALDH1A1CA12 | |
| SCHEMBL10382417 | 0.73 | ALDH1A1 (0.51) | POLBTP53ALDH1A1HTTHPGD | |
| SCHEMBL12350707 | 0.72 | MAP4K4 (0.40) | L3MBTL1ALDH1A1HTTHPGDGAA | |
| SCHEMBL12350692 | 0.72 | NAMPT (0.37) | L3MBTL1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114381-B2 | Radiolabeled compounds and compositions, their precursors and methods for their production | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-02-14 | — | — | US | disclosed |
| US-20080038191-A1 | Radiolabeled Compounds And Compositions, Their Precursors And Methods For Their Production | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080038191-A1 | Radiolabeled Compounds And Compositions, Their Precursors And Methods For Their Production | GMNN, MEN1, NCLN | L3MBTL1 2348/4885CA1 441/4885CA2 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.